HINOON Stock Overview
Manufactures, imports, sells, exports, and markets pharmaceutical and allied consumer products. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for HINOON from our risk checks.
Highnoon Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | PK₨925.22 |
| 52 Week High | PK₨1,000.00 |
| 52 Week Low | PK₨444.40 |
| Beta | 0.19 |
| 11 Month Change | 18.80% |
| 3 Month Change | 21.03% |
| 1 Year Change | 96.28% |
| 33 Year Change | 106.95% |
| 5 Year Change | 176.36% |
| Change since IPO | 25,892.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| HINOON | PK Pharmaceuticals | PK Market | |
|---|---|---|---|
| 7D | 5.1% | 1.9% | 2.1% |
| 1Y | 96.3% | 126.5% | 43.4% |
Return vs Industry: HINOON underperformed the PK Pharmaceuticals industry which returned 126.5% over the past year.
Return vs Market: HINOON exceeded the PK Market which returned 43.4% over the past year.
Price Volatility
| HINOON volatility | |
|---|---|
| HINOON Average Weekly Movement | 4.6% |
| Pharmaceuticals Industry Average Movement | 6.5% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in PK Market | 9.6% |
| 10% least volatile stocks in PK Market | 3.8% |
Stable Share Price: HINOON has not had significant price volatility in the past 3 months compared to the PK market.
Volatility Over Time: HINOON's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 2,295 | Adeel Haider | www.highnoon-labs.com |
Highnoon Laboratories Limited, together with its subsidiaries, manufactures, imports, sells, exports, and markets pharmaceutical and allied consumer products. It offers products in various therapeutic areas, including allergy, anti-infective, cardiology, gastroenterology, metabolic, musculoskeletal, obstetrics and gynaecology, paediatrics, respiratory, and urology; and generic products under various brands. The company serves Pakistan, Afghanistan, the United Arab Emirates, France, Kenya, Iraq, Cambodia, Tanzania, and internationally.
Highnoon Laboratories Limited Fundamentals Summary
| HINOON fundamental statistics | |
|---|---|
| Market cap | PK₨48.32b |
| Earnings (TTM) | PK₨3.02b |
| Revenue (TTM) | PK₨23.02b |
16.2x
P/E Ratio2.1x
P/S RatioIs HINOON overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HINOON income statement (TTM) | |
|---|---|
| Revenue | PK₨23.02b |
| Cost of Revenue | PK₨11.38b |
| Gross Profit | PK₨11.64b |
| Other Expenses | PK₨8.62b |
| Earnings | PK₨3.02b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 56.98 |
| Gross Margin | 50.57% |
| Net Profit Margin | 13.11% |
| Debt/Equity Ratio | 8.4% |
How did HINOON perform over the long term?
See historical performance and comparison